Patriot Coal (NYSE: PCX), Petrohawk Energy (NYSE: HK), DeVry Inc. (NYSE: DV), AngioDynamics (NASDAQ: ANGO) and Pharmaceutical Product Development (NASDAQ: PPDI) upgraded by analysts.
Canaccord Genuity upgraded AngioDynamics (ANGO) from a “Hold” rating to a “Buy” rating. They have a price target of $16.50 on the company, up from $15.00.
UBS AG (NYSE: UBS) upgraded DeVry Inc. (DV) from a “Neutral” rating to a “Buy” rating. They have a price target of $75.00 on the company, up from $55.00.
Lazard Capital upgraded Petrohawk Energy (HK) was upgraded by analysts at from a “Sell” rating to a “Neutral” rating.
BMO Capital Markets upgraded Patriot Coal (PCX) to a “Market Perform” rating.
William Blair upgraded Pharmaceutical Product Development (PPDI) from a “Market Perform” rating to an “Outperform” Rating.
Showing posts with label Pharmaceutical Product Development. Show all posts
Showing posts with label Pharmaceutical Product Development. Show all posts
Monday, July 18, 2011
Friday, May 20, 2011
Dividends on (KNX) (MO) (MPW) (PPDI) (RDK) Declared
Knight Transportation Inc. (NYSE:KNX), Altria Group Inc. (NYSE:MO), Medical Properties Trust (NYSE:MPW), Pharmaceutical Product Development (NASDAQ:PPDI) and Ruddick Corp. (NYSE:RDK) declare dividends.
The Board of Directors of Knight Transportation Inc. (KNX) declared a quarterly common stock dividend of $0.06 per share payable 6/24/11 to shareholders of record at the close of business on 6/3/11.
The Board of Directors of Altria Group Inc. (MO) declared a quarterly common stock dividend of $0.38 per share payable 7/11/11 to shareholders of record at the close of business on 6/15/11.
The Board of Directors of Medical Properties Trust (MPW) declared a quarterly common stock dividend of $0.20 per share payable 7/14/11 to shareholders of record at the close of business on 6/16/11.
The Board of Directors of Pharmaceutical Product Development (PPDI) declared a second quarter common stock dividend of $0.15 per share payable 6/29/11 to shareholders of record at the close of business on 6/15/11.
The Board of Directors of Ruddick Corp. (NYSE:RDK) declared a quarterly common stock dividend of $0.13 per share payable 7/1/11 to shareholders of record at the close of business on 6/10/11.
The Board of Directors of Knight Transportation Inc. (KNX) declared a quarterly common stock dividend of $0.06 per share payable 6/24/11 to shareholders of record at the close of business on 6/3/11.
The Board of Directors of Altria Group Inc. (MO) declared a quarterly common stock dividend of $0.38 per share payable 7/11/11 to shareholders of record at the close of business on 6/15/11.
The Board of Directors of Medical Properties Trust (MPW) declared a quarterly common stock dividend of $0.20 per share payable 7/14/11 to shareholders of record at the close of business on 6/16/11.
The Board of Directors of Pharmaceutical Product Development (PPDI) declared a second quarter common stock dividend of $0.15 per share payable 6/29/11 to shareholders of record at the close of business on 6/15/11.
The Board of Directors of Ruddick Corp. (NYSE:RDK) declared a quarterly common stock dividend of $0.13 per share payable 7/1/11 to shareholders of record at the close of business on 6/10/11.
Friday, January 21, 2011
Pharmaceutical Product Development (NASDAQ:PPDI) Gives Strong 2011 Guidance
Guidance from Pharmaceutical Product Development (NASDAQ:PPDI) gave impetus to the shares Thursday, and appears to has sustainability.
Jefferies noted, "As a result (of guidance), a muted reaction or even some profit-taking would not be surprising. The company's fundamentals seem in order, in our view, revenue is accelerating and margins should expand helping to drive earnings. We believe the growth story remains intact."
Jefferies boosted their full year 2011 EPS and revenue estimates from $1.49 and $1.5 billion to $1.60 and $1.54 billion in response to the guidance.
They maintain their "Buy" rating on Pharmaceutical Product Development (PPDI), which closed Thursday at $29.33, gaining $0.90, or 3.17 percent. Jefferies raised their price target on PPDI from $29 to $32.
Jefferies noted, "As a result (of guidance), a muted reaction or even some profit-taking would not be surprising. The company's fundamentals seem in order, in our view, revenue is accelerating and margins should expand helping to drive earnings. We believe the growth story remains intact."
Jefferies boosted their full year 2011 EPS and revenue estimates from $1.49 and $1.5 billion to $1.60 and $1.54 billion in response to the guidance.
They maintain their "Buy" rating on Pharmaceutical Product Development (PPDI), which closed Thursday at $29.33, gaining $0.90, or 3.17 percent. Jefferies raised their price target on PPDI from $29 to $32.
Subscribe to:
Posts (Atom)